SAB Biotherapeutics Q2 2023 Earnings Report

SAB Biotherapeutics EPS Results

• Actual EPS: -$0.14
• Consensus EPS: -$0.14
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

SAB Biotherapeutics Revenue Results

• Actual Revenue: $0.09 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

SAB Biotherapeutics Announcement Details

• Quarter: Q2 2023
• Date: 8/21/2023
• Time: Q2 2023 Earnings Release

SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.